IBA Announces First Patient Treated in ConformalFLASH Proton Therapy Trial

• IBA announced October 21, 2026, that the first patient received ConformalFLASH proton therapy in its sponsored C-FLASH-01 trial at Penn Medicine.
• The first human feasibility study evaluates treatment delivery in patients requiring repeat radiation therapy for head and neck cancer.
• The trial operates under an FDA-authorized Investigational Device Exemption; potential clinical benefits remain under investigation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBA - Ion Beam Applications SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210100OMX_____CNEWS_EN_GNW1001278967_en) on October 21, 2026, and is solely responsible for the information contained therein.